Warning
In the context of Covid-19 and following the general confinement of people in
We inform you that the general meeting will be held without the physical presence of the shareholders, and we ask you to cast your vote remotely or to give your proxy to the chairman.
You are invited to regularly consult the company's website: www.gensight-biologics.com
In addition, within the framework of the relationship between the company and its shareholders, the company strongly invites them to favor the transmission of all their requests and documents by electronic means to the following address: ir@gensight-biologics.com.
The company is warning its shareholders that, given current traffic restrictions, it may not be able to receive postal items addressed to it.
The notice containing the agenda and draft resolutions was published in the French BALO on
The preparatory documents for the General Meeting listed in Article R. 225-73-1 of the French Commercial Code are posted on the company's website (www.gensight-biologics.com) in the Investors, Documentation section.
The preparatory documents for the General Meeting will also be made available to shareholders as of the convening of the meeting. Thus, in accordance with applicable regulatory provisions: All registered shareholders may, until five days (included) before the meeting, request by email that the Company sends the documents referred to in Articles L. 225-115 and R. 225-83 of the French Commercial Code. For holders of bearer shares, the exercise of this right is subject to the provision of a certificate of participation in the bearer share accounts held by the authorized intermediary; Any shareholder may consult the documents referred to in Articles L. 225-115 and R. 225-83 of the French Commercial Code on the company's website.
About
Contact:
Thomas Gidoin
Tel: +33 (0)1 76 21 72 20
Email: tgidoin@gensight-biologics.com
(C) 2020 Electronic News Publishing, source